Last updated on February 2018

Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC)


Brief description of study

Purpose The TARGET All comers trial is a prospective, multicenter, randomized, two-arm, non-inferiority, open-label study with 1656 patients at 20 centers in Europe. The study is a "real world, all comers" study.

Detailed Study Description

Primary objective: to compare the MicroPort Medical (Group) Co., Ltd Firehawkcobalt chromium coronary stent ( rapamycin target eluting ) system with abluminal grooves containing a biodegradable polymer with the Abbott XIENCE family EES (Everolimus-Eluting stent) system with respect to cardiac death, myocardial infarction (not clearly attributable to a non-target vessel), Target Lesion Revascularization at 1 year in a "real world" patient population.

Clinical Study Identifier: NCT02520180

Contact Investigators or Research Sites near you

Start Over

Lene Holmvang, MD

Rigshospitalet
Copenhagen, Denmark
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.